Alnylam Pharmaceuticals Inc (ALNY)

Alnylam Pharmaceuticals Inc Stock (ALNY) Financials Data

*All numbers in millions

Period End Date	2026-09-30	2026-06-30	2025-12-31	2025-09-30	2025-06-30
Period Length	3 Months	3 Months	3 Months	3 Months	3 Months
Revenues	12.95%1,458.09	1,290.95	1,097.03	1,249.03	773.69
Cost Of Revenue	21.29%361.75	298.26	267.72	197.23	142.03
	1.70%342.00	347.92	-	-	-
Selling, General, and Administrative	1.70%342.00	347.92	-	-	-
Research and Development	1.11%408.54	413.13	-	-	-
Costs And Expenses	4.98%1,112.29	1,059.51	965.32	881.04	789.89
Operating Income/Loss	49.41%345.80	231.44	131.72	367.98	-16.20
Nonoperating Income/Loss	6.80%-49.99	-53.64	-45.46	-129.01	-19.16
Income/Loss From Continuing Operations Before Tax	66.37%295.81	177.81	86.26	238.97	-35.36
Income Tax Expense/Benefit, Deferred	-1,894.73	-	-27.17	5.60	9.74
Income Tax Expense/Benefit	14,159%-1,871.53	13.31	-25.28	-12.12	30.92
	1,218%2,167.34	164.49	111.54	251.08	-66.28
Attributable To Parent	1,218%2,167.34	164.49	111.54	251.08	-66.28
Basic Average Shares	0.17%133.83	133.61	0.41	131.45	130.63
Diluted Average Shares	0.17%138.04	138.28	0.54	137.35	130.63
Basic Earnings Per Share	1,216%16.19	1.23	0.84	1.91	-0.51
Diluted Earnings Per Share	1,199%15.72	1.21	0.82	1.84	-0.51